logo image
search icon
KRAS Inhibitors Market

KRAS Inhibitors Market Size, Share & Trends Analysis Report By Cancer Type (Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Others), By End-Use (Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, Others), By Region, And By Segment Forecasts, 2023-2031.

Report ID : 2251 | Published : 2023-12-04 | Pages: 180 | Format: PDF/EXCEL

KRAS Inhibitors Market Size is valued at USD 97.8 Mn in 2022 and is predicted to reach USD 157.6 Mn by the year 2031 at a 5.61% CAGR during the forecast period for 2023-2031.

KRAS Inhibitors Market

Kirsten rat sarcoma viral oncogene homolog inhibitor genes encode a protein in many cell signalling pathways. Several cancers, including lung, colorectal, and pancreatic cancers, often include mutations in the KRAS gene. Carcinogenesis, or the unchecked growth of cells, can result from these alterations. A group of medications known as KRAS inhibitors has been developed to block the signalling pathways connected with the mutant KRAS protein. By blocking the aberrant cellular signalling brought on by the mutant KRAS gene, these medications hope to decrease the rate of cancer cell proliferation and metastasis. Kirsten rat sarcoma has become more necessary due to the rising incidence of lung cancer (KRAS). Recent advances in pharmaceutical research and the creation of novel anti-cancer drugs have contributed to the growth of the Kirsten rat sarcoma (KRAS) industry. These variables are expected to drive the market's expansion in the time allotted. Furthermore, Innovations in structure-based drug design and identifying new inhibitors have paved the way for creating potent KRAS inhibitors, which should lead to further market expansion.

However, the market growth is hampered by the strict regulatory criteria for the safety and health of the KRAS inhibitors market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity KRAS inhibitors, a potential obstacle to market expansion could be the impatience with which the benefits of Kirsten rat sarcoma (KRAS) research are acknowledged. It is costly to pay for diagnostic tests performed in hospitals and labs. Critical investigations are still in progress. All of these factors have the potential to impede the market's growth. The pandemic of COVID-19 has highlighted the urgent need to hasten the creation of cancer care technology and encourage worldwide cooperation to tackle global health issues. Therefore, some of these challenges are anticipated to become more handleable and ultimately overcome in a post-COVID environment.

Competitive Landscape

Some Major Key Players In The KRAS Inhibitors Market:

  • Amgen
  • Boehringer Ingelheim
  • BridgeBio Pharma
  • Erasca
  • Innovent Biologics, Inc.
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology, Inc.
  • Roche
  • Genentech
  • Verastem Oncology
  • Revolution Medicines
  • Immuneering Corporation
  • Jacobio Pharmaceuticals
  • Deciphera Pharmaceuticals
  • Elicio Therapeutics
  • InventisBio
  • Gritstone Bio
  • D3 Bio
  • Others

Market Segmentation:

The KRAS inhibitors market is segmented based on cancer type and end-use. According to cancer type, the market is segmented into lung cancer, pancreatic cancer, colorectal cancer, and others. By end-use, the market is segmented into clinic laboratories, cancer diagnostic centres, hospitals, cancer research institutes, academic institutions, and others.

Based On The Cancer Type, The Lung Cancer KRAS Inhibitors Market Segment Is Accounted As A Major Contributor To The KRAS Inhibitors Market.

The Lung cancer KRAS inhibitors market is expected to hold a major global market share in 2022. Lung cancer patients have a disproportionately high number of KRAS mutations, which presents a substantial opportunity for the KRAS inhibitor market. Many lung cancer patients may find successful therapy choices if these mutations are targeted. There is a big, unfulfilled medical need for effective treatments for lung cancer, especially non-small cell lung cancer (NSCLC), which is a difficult illness to treat. There is a current medical need to treat KRAS-mutant lung cancer, and KRAS inhibitors provide a potential way to target these mutations precisely.

Cancer Research Institutes Segment To Witness Growth At A Rapid Rate.

Cancer research institutes make up the bulk of KRAS inhibitors because of the growing number of collaborations between research institutions and biotech businesses and the expansion of clinical research, especially in countries like the US, Germany, the UK, China, and India. 

In The Region, The North American KRAS Inhibitors Market Holds A Significant Revenue Share.

The North American KRAS inhibitors market is expected to register the maximum market share in revenue in the near future. It can be attributed to the demand for targeted treatments in oncology, improvements in healthcare infrastructure, the frequency of KRAS mutations in different cancer types, and the pace of drug discovery and development, all potential drivers of market expansion in this field. In addition, Asia Pacific is estimated to grow rapidly in the global KRAS inhibitors market because the ageing population and the rising desire for effective treatment through personalized medicine are expected to propel the growth of regional markets in the next year. The region's market is anticipated to experience expansion due to the increasing emphasis on biotechnology and its technological advancements.

Recent Developments:

  • In October 2022, At the AACR annual meeting, Novartis presented encouraging clinical results for JDQ443, an experimental selective, covalent, and orally accessible KRASG12C inhibitor. A poster on Wednesday, April 13, and Cancer Discovery1 provide detailed information about JDQ443's discovery. JDQ443, discovered at Novartis, showed anti-tumor activity, high systemic exposure at its necessory dose, and a favorable safety profile in patients with KRAS G12C-mutated solid tumors in Phase Ib of the KontRASt-01 study (NCT04699188)2. In an oral session, the late-breaking abstract data will be presented.
  • In September 2023, Amgen reported promising results from a specific part of the CodeBreaK 101 clinical trial, which is a Phase 1b research investigating the effectiveness of LUMAKRAS® (sotorasib) in combination with carboplatin and pemetrexed for treating adult patients with advanced non-small cell lung cancer (NSCLC) that contains a specific genetic mutation called KRAS G12C. The aforementioned findings were presented orally at the 2023 World Conference on Lung Cancer (WCLC), organized by the IASLC.

KRAS Inhibitors Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 97.8 Mn

Revenue Forecast In 2031

USD 157.6 Mn

Growth Rate CAGR

CAGR of 5.61 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Mn and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Cancer Type, End-User

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Competitive Landscape

Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics Inc., Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology, Inc., Roche, Genentech, Verastem Oncology, Revolution Medicines, Immuneering Corporation, Jacobio Pharmaceuticals, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio and Others

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global KRAS Inhibitors Market Snapshot

Chapter 4. Global KRAS Inhibitors Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Cancer Type Estimates & Trend Analysis

5.1. By Cancer Type, & Market Share, 2020 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Cancer Type:

5.2.1. Lung Cancer

5.2.2. Pancreatic Cancer

5.2.3. Colorectal Cancer

5.2.4. Others

Chapter 6. Market Segmentation 2: By End-Use Estimates & Trend Analysis

6.1. By End-Use & Market Share, 2020 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By End-Use:

6.2.1. Clinic Laboratories

6.2.2. Cancer Diagnostic Centers

6.2.3. Hospitals

6.2.4. Cancer Research Institutes

6.2.5. Academic Institutions

6.2.6. Others

Chapter 7. KRAS Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America KRAS Inhibitors Market revenue (US$ Million) estimates and forecasts By Cancer Type, 2019-2031

7.1.2. North America KRAS Inhibitors Market revenue (US$ Million) estimates and forecasts By End-Use, 2019-2031

7.1.3. North America KRAS Inhibitors Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

7.2. Europe

7.2.1. Europe KRAS Inhibitors Market revenue (US$ Million) By Cancer Type, 2019-2031

7.2.2. Europe KRAS Inhibitors Market revenue (US$ Million) By End-Use, 2019-2031

7.2.3. Europe KRAS Inhibitors Market revenue (US$ Million) by country, 2019-2031

7.3. Asia Pacific

7.3.1. Asia Pacific KRAS Inhibitors Market revenue (US$ Million) By Cancer Type, 2019-2031

7.3.2. Asia Pacific KRAS Inhibitors Market revenue (US$ Million) By End-Use, 2019-2031

7.3.3. Asia Pacific KRAS Inhibitors Market revenue (US$ Million) by country, 2019-2031

7.4. Latin America

7.4.1. Latin America KRAS Inhibitors Market revenue (US$ Million) By Cancer Type, (US$ Million) 2019-2031

7.4.2. Latin America KRAS Inhibitors Market revenue (US$ Million) By End-Use, (US$ Million) 2019-2031

7.4.3. Latin America KRAS Inhibitors Market revenue (US$ Million) by country, 2019-2031

7.5. Middle East & Africa

7.5.1. Middle East & Africa KRAS Inhibitors Market revenue (US$ Million) By Cancer Type, (US$ Million) 2019-2031

7.5.2. Middle East & Africa KRAS Inhibitors Market revenue (US$ Million) By End-Use, (US$ Million) 2019-2031

7.5.3. Middle East & Africa KRAS Inhibitors Market revenue (US$ Million) by country, 2019-2031

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Amgen

8.2.2. Boehringer Ingelheim

8.2.3. BridgeBio Pharma

8.2.4. Erasca

8.2.5. Innovent Biologics, Inc.

8.2.6. Incyte

8.2.7. Mirati Therapeutics

8.2.8. Novartis

8.2.9. Jemincare

8.2.10. Cardiff Oncology,Inc.

Segmentation of KRAS Inhibitors Market-

KRAS Inhibitors Market By Cancer Type-

  • Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Others

KRAS Inhibitors Market Seg

KRAS Inhibitors Market By End-User-

  • Clinic Laboratories
  • Cancer Diagnostic Centers
  • Hospitals
  • Cancer Research Institutes
  • Academic Institutions
  • Others

KRAS Inhibitors Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the KRAS Inhibitors Market?

KRAS Inhibitors Market expected to grow at a 5.61% CAGR during the forecast period for 2023-2031.

Revolution Medicines, Immuneering Corporation, Jacobio Pharmaceuticals, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach